The Evolving Landscape of Contemporary Cancer Therapies

Dear Colleagues,

A new era of cancer therapeutic modalities, including immunotherapies and targeted therapies, has led to a paradigm shift in cancer treatment, inducing effective and durable clinical responses for a significant number of patients suffering from various types of malignancy. Combinatorial treatments, including immune checkpoint inhibitors, adoptive cellular therapies, molecular targeted therapies, and cancer vaccines have overcome cancer heterogeneity, inducing resistance mechanisms, and thus reinforcing the impact of these novel cancer therapeutic approaches. However, despite this success, a substantial number of patients do not respond to these therapeutic regimens, which underlines the necessity of determining ways to predict the clinical responses to treatment. The 9th Symposium on Advances in Cancer Immunology and Immunotherapy, which will be held on November 30–December 2 2023 in Athens, plans to address multidisciplinary issues related to cancer immunology and immunotherapy spanning basic and translational research with the ultimate aim to design the most effective cancer therapeutic strategies. The scientific objectives of the conference are the following: (a) discovering predictive biomarkers for cancer immunotherapies and targeted therapies; (b) improving the mechanisms of action that are implicated in the immunotherapeutic and targeted modalities associated with the treatment of malignancy; (c) presenting results from clinical trials investigating the efficacy and safety of cancer immunotherapy and targeted therapy regimens; and (d) presenting strategies for immunomodulation, counteracting resistance, and mitigating adverse events. The conference will feature world-renowned oncologists and researchers, who will provide their insights on the above topics, in an effort to enhance our understanding of tumor evolution and design-enhanced treatment strategies.

Dr. Constantin N. Baxevanis
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Onco is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer immunotherapy
• targeted cancer therapies
• immune resistance
• immunomodulation
• cancer biomarkers